Now showing items 1-2 of 2
Identifying Combinatorial Drug Targets for Ras Pathway-Driven Melanomas
Cutaneous melanoma is a highly metastatic skin cancer, with ~100,000 new cases estimated to occur in 2020 in the US. Melanomas are defined by oncogenic “driver” mutations that constitutively activate the Ras/Raf/MEK/ERK ...
Context-Dependent Requirements for Mitochondrial Apoptosis in CAR T Killing of Cancer Cells
Chimeric antigen receptor (CAR) T cell therapy is now an FDA approved treatment for several hematologic malignancies, yet not all patients respond to this treatment. While some resistance mechanisms have been identified, ...